| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institute of Cancer Research, Drug Development Section, Clinical Pharmacology Team, Block E. 15 Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, United Kingdom [M. I. W.]; Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH Bethesda, Maryland 20892 [D. W., P. M. O., K. W. K.]; and Department of Medicine and Molecular Microbiology, Howard Hughes Medical Institute, Washington University School of Medicine, St Louis, Missouri 63110 [D. H., S. J. K.]
Bcl-2 is a novel protooncogene which prolongs cell survival and suppresses apoptosis. We examined whether constitutive expression of transfected human bcl-2 conferred resistance to two different DNA damaging drugs, nitrogen mustard (HN2) and camptothecin (CPT) in a murine, IL-3 dependent cell line (FL5.12). HN2 treatment produced 2-fold less cell death and DNA degradation in cells overexpressing bcl-2 relative to control cells transfected with a construct bearing only the neoR gene. DNA degradation was characterized by oligonucleosomal length fragments indicating that programmed cell death or apoptosis had occurred. Equimolar HN2 produced similar extents of interstrand cross-link formation and repair in each cell line. Cell cycle characteristics were similar for both cell lines following equimolar HN2 treatment, exhibiting a brief S phase delay followed by a longer G2 arrest. Time course studies indicated that DNA fragmentation occurred following peak G2 arrest in control cells and 12 h later in bcl-2 transfected cells. Equimolar CPT exposure also induced 2-fold less death and apoptotic DNA fragmentation in bcl-2 transfected compared to control cells. DNA single strand break formation and resealing kinetics were comparable in both cell lines following equimolar CPT treatment. CPT caused similar cell cycle perturbations in both cell lines, with a brief S phase block detectable 12 h after an equimolar drug dose. Kinetic studies showed apoptosis occurred following maximal S phase arrest in control and 12 h later in bcl-2 transfected cells. By contrast, IL-3 withdrawal produced rapid and extensive DNA degradation and apoptosis in controls 24 h postwithdrawal, and this process was inhibited 3–4-fold in bcl-2 transfectants. Cell cycle analysis showed both cell lines arrested in G0/G1 following IL-3 removal. In summary, bcl-2 transfection affords a 2-fold protection from HN2 and CPT cytotoxicity and decreases drug induced apoptosis in FL5.12 cells, despite the different mechanisms of action and cell cycle effects of each agent. Bcl-2 overexpression appears to represent a novel drug resistance mechanism of potential clinical significance.
1 To whom all correspondence should be addressed.
Received 10/19/92. Accepted 2/11/93.
This article has been cited by other articles:
|
|
 |
|
  C. M. Rudin, R. Salgia, X. Wang, L. D. Hodgson, G. A. Masters, M. Green, and E. E. Vokes Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 J. Clin. Oncol., February 20, 2008; 26(6): 870 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liu, J.-Y. Ahn, X. Liu, and K. Ye Ebp1 isoforms distinctively regulate cell survival and differentiation PNAS, July 18, 2006; 103(29): 10917 - 10922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Mita, L. Ochoa, E. K. Rowinsky, J. Kuhn, G. Schwartz, L. A. Hammond, A. Patnaik, I.-T. Yeh, E. Izbicka, K. Berg, et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (GenasenseTM, G3139) and irinotecan in patients with metastatic colorectal cancer Ann. Onc., February 1, 2006; 17(2): 313 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Tolcher, K. Chi, J. Kuhn, M. Gleave, A. Patnaik, C. Takimoto, G. Schwartz, I. Thompson, K. Berg, S. D'Aloisio, et al. A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3854 - 3861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Tolcher, J. Kuhn, G. Schwartz, A. Patnaik, L. A. Hammond, I. Thompson, H. Fingert, D. Bushnell, S. Malik, J. Kreisberg, et al. A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5048 - 5057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Raffo, J. C. Lai, C. A. Stein, P. Miller, S. Scaringe, A. Khvorova, and L. Benimetskaya Antisense RNA Down-Regulation of bcl-2 Expression in DU145 Prostate Cancer Cells Does Not Diminish the Cytostatic Effects of G3139 (Oblimersen) Clin. Cancer Res., May 1, 2004; 10(9): 3195 - 3206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Rudin, M. Kozloff, P. C. Hoffman, M. J. Edelman, R. Karnauskas, R. Tomek, L. Szeto, and E. E. Vokes Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer J. Clin. Oncol., March 15, 2004; 22(6): 1110 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Lai, L. Benimetskaya, R. M. Santella, Q. Wang, P. S. Miller, and C. A. Stein G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner Mol. Cancer Ther., October 1, 2003; 2(10): 1031 - 1043. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. K. Roy, Y. Kuwabara, K. Hara, Y. Watanabe, and Y. Tamai Peptides From the N-terminal End of Bovine Lactoferrin Induce Apoptosis in Human Leukemic (HL-60) Cells J Dairy Sci, September 1, 2002; 85(9): 2065 - 2074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Rudin, G. A. Otterson, A. M. Mauer, M. A. Villalona-Calero, R. Tomek, B. Prange, C. M. George, L. Szeto, and E. E. Vokes A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer Ann. Onc., April 1, 2002; 13(4): 539 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Mao, H. Xiang, J. Wang, S. Korsmeyer, J. Reddan, and D. W.-C. Li Human bcl-2 Gene Attenuates the Ability of Rabbit Lens Epithelial Cells against H2O2-induced Apoptosis through Down-regulation of the alpha B-crystallin Gene J. Biol. Chem., November 9, 2001; 276(46): 43435 - 43445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Boushey, B. Yusta, and D. J. Drucker Glucagon-like Peptide (GLP)-2 Reduces Chemotherapy-associated Mortality and Enhances Cell Survival in Cells Expressing a Transfected GLP-2 Receptor Cancer Res., January 1, 2001; 61(2): 687 - 693. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. J. Klasa, A. F. List, and B. D. Cheson Rational Approaches to Design of Therapeutics Targeting Molecular Markers Hematology, January 1, 2001; 2001(1): 443 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lavarino, S. Pilotti, M. Oggionni, L. Gatti, P. Perego, G. Bresciani, M. A. Pierotti, G. Scambia, G. Ferrandina, A. Fagotti, et al. p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma J. Clin. Oncol., December 1, 2000; 18(23): 3936 - 3945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filipits, U. Jaeger, I. Simonitsch, C. Chizzali-Bonfadin, H. Heinzl, and R. Pirker Clinical Relevance of the Lung Resistance Protein in Diffuse Large B-Cell Lymphomas Clin. Cancer Res., September 1, 2000; 6(9): 3417 - 3423. [Abstract] [Full Text]
|
|
|
|
|
|
D. E. Lopes de Menezes, N. Hudon, N. McIntosh, and L. D. Mayer Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin Clin. Cancer Res., July 1, 2000; 6(7): 2891 - 2902. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Klasa, M. B. Bally, R. Ng, J. H. Goldie, R. D. Gascoyne, and F. M. P. Wong Eradication of Human Non-Hodgkin's Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide Clin. Cancer Res., June 1, 2000; 6(6): 2492 - 2500. [Abstract] [Full Text]
|
|
|
|
|
|
W. H. Wilson, L. Sorbara, W. D. Figg, E. K. Mont, E. Sausville, K. E. Warren, F. M. Balis, K. Bauer, M. Raffeld, A. M. Senderowicz, et al. Modulation of Clinical Drug Resistance in a B Cell Lymphoma Patient by the Protein Kinase Inhibitor 7-Hydroxystaurosporine: Presentation of a Novel Therapeutic Paradigm Clin. Cancer Res., February 1, 2000; 6(2): 415 - 421. [Abstract] [Full Text]
|
|
|
|
|
|
B. Guo, S. Cao, K. Tóth, R. G. Azrak, and Y. M. Rustum Overexpression of Bax Enhances Antitumor Activity of Chemotherapeutic Agents in Human Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., February 1, 2000; 6(2): 718 - 724. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. A. Hogarth and A. G. Hall Increased BAX Expression Is Associated With an Increased Risk of Relapse in Childhood Acute Lymphocytic Leukemia Blood, April 15, 1999; 93(8): 2671 - 2678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ohguchi, A. Ishisaki, N. Okahashi, M. Koide, T. Koseki, K. Yamato, T. Noguchi, and T. Nishihara Actinobacillus actinomycetemcomitans Toxin Induces Both Cell Cycle Arrest in the G2/M Phase and Apoptosis Infect. Immun., December 1, 1998; 66(12): 5980 - 5987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-z. Su, M. T. Madireddi, J. J. Lin, C. S. H. Young, S. Kitada, J. C. Reed, N. I. Goldstein, and P. B. Fisher The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice PNAS, November 24, 1998; 95(24): 14400 - 14405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ye, Y. Ke, N. Keshava, J. Shanks, J. A. Kapp, R. R. Tekmal, J. Petros, and H. C. Joshi Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells PNAS, February 17, 1998; 95(4): 1601 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-G. Wang, C. F. Johnston, J. J. Marley, K. V. Phenix, A. B. Atkinson, C. F. J. Russell, and K. D. Buchanan Expression of the Apoptosis-Suppressing Gene BCL-2 in Pheochromocytoma is Associated with the Expression of C-MYC J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1949 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Hollander, Q. Zhan, I. Bae, and A. J. Fornace Jr. Mammalian GADD34, an Apoptosis- and DNA Damage-inducible Gene J. Biol. Chem., May 23, 1997; 272(21): 13731 - 13737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Wilson, J. Teruya-Feldstein, T. Fest, C. Harris, S. M. Steinberg, E. S. Jaffe, and M. Raffeld Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas Blood, January 15, 1997; 89(2): 601 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhou, L. Qian, K. M. Kozopas, and R. W. Craig Mcl-1, a Bcl-2 Family Member, Delays the Death of Hematopoietic Cells Under a Variety of Apoptosis-Inducing Conditions Blood, January 15, 1997; 89(2): 630 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Minn, L. H. Boise, and C. B. Thompson Bcl-x(S) Antagonizes the Protective Effects of Bcl-x(L) J. Biol. Chem., March 15, 1996; 271(11): 6306 - 6312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Chen and D. V. Faller Phosphorylation of Bcl-2 Protein and Association with p21[IMAGE] in Ras-induced Apoptosis J. Biol. Chem., February 2, 1996; 271(5): 2376 - 2379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Merritt, C. Potten, A. Watson, D. Loh, K Nakayama, K Nakayama, and J. Hickman Differential expression of bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia J. Cell Sci., January 6, 1995; 108(6): 2261 - 2271. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
